This move is archived. Current quotes and coverage live on the stock page.
Get MSCL alerts:
Satellos Bioscience Inc. shares surged by 3.54% in the latest trading session, reflecting positive investor sentiment.
In the most recent trading session, Satellos Bioscience Inc. (MSCL.TO) saw its stock rise by 3.54%, closing at CA$8.49. This increase comes as the company makes progress in its clinical programs, especially with its lead candidate, SAT-3247, which targets Duchenne muscular dystrophy.
Advertisement
Satellos Bioscience Inc.
MSCL.TO
MSCL.TO
Satellos Bioscience Inc.
WealthAwesomeMarket cap
$280.06M
52W high
$18.98
52W low
$7.32
1W change
+11.17%
Beta
1.14
Analyst Price Targets
Based on analyst covering MSCL
Wall Street analysts forecast MSCL stock price to rise 26.8% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$17.67
+26.8% Upside
Current Price
C$13.93
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MSCL's historical volatility
30-Day Vol
50.7%
Annualized
90-Day Vol
72.5%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$16.65
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$14.78 | C$12.41 โ C$17.61 |
| 60 trading days | C$15.69 | C$12.25 โ C$20.09 |
| 90 trading days | C$16.65 | C$12.30 โ C$22.54 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors are optimistic about the advancements in Satellos' clinical trials, which could lead to future growth and increased interest in the market.
CA$8.49
With a market cap of CA$170.8 million, Satellos operates in a niche market that has significant growth potential, particularly if its clinical trials yield positive results.
Bull case
The successful launch of the BASECAMP Phase 2 clinical trial for SAT-3247 could greatly improve Satellos' position in the market and attract more investment, especially if the trial results continue to show promise.
Bear case
As a small-cap biotech firm, Satellos faces risks, including the chance of clinical trial failures or delays, which could hurt investor confidence and affect stock performance.
Market Performance Overview
Advertisement
Satellos Bioscience Inc. experienced a 3.54% increase in its stock price, closing at CA$8.49. This rise indicates growing optimism among investors about the company's clinical prospects, especially regarding its recent advancements in treating Duchenne muscular dystrophy.
Clinical Developments Driving Interest
The start of the BASECAMP Phase 2 clinical trial for SAT-3247 has been a key factor in the stock's performance. As Satellos progresses with its clinical programs, investors are keeping a close eye on the outcomes, which could lead to further stock appreciation if the results are favorable. For more insights on the company's recent activities, check out our detailed analysis on Satellos Bioscience.
Looking Ahead
As a small-cap biotech company, Satellos is navigating a landscape filled with both opportunities and challenges. Investors should stay alert to the risks associated with clinical trials while also considering the significant upside if the company's treatments prove effective. For ongoing updates, visit our Satellos stock page for the latest information.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
